Multibagger pharma penny stock under Rs 40: Company receives authorisation as Integra's authorised DGAFMS distributor
DSIJ Intelligence-1 / 04 Dec 2025/ Categories: Multibaggers, Penny Stocks, Trending
The stock gave multibagger returns of 4,600 per cent in 3 years and a whopping 21,500 per cent in 5 years.
Shukra Pharmaceuticals Limited has announced a significant development, as per Regulation 30 of the SEBI Listing Regulations, by disclosing the receipt of an Authorisation Letter on December 3, 2025, from Integra Medical Devices India Private Limited. This letter officially designates Shukra Pharmaceuticals as the Authorised Distributor for all DGAFMS (Directorate General Armed Forces Medical Services) purchases across India. Under this authorisation, which is valid until December 31, 2026, the company is empowered to promote, market, and supply Integra's medical equipment and devices for all DGAFMS-affiliated projects, including those across Defence Hospitals, Commands, and related Defence Organisations nationwide, and to operate as the official distributor for all DGAFMS-related procurement activities.
This strategic authorisation is expected to have a significant positive impact on Shukra Pharmaceuticals and its shareholders. The move strengthens the company's presence in the high-value Defence Healthcare segment, known for consistent demand and long-term contracts, while simultaneously expanding its product portfolio into advanced medical devices through the partnership with Integra Medical Devices. The collaboration is anticipated to enhance revenue visibility and improve margins due to the premium nature of the medical device offerings. Ultimately, this collaboration positions Shukra Pharma as a credible partner for future Government and Defence-sector projects, creating opportunities for sustainable business growth and positively contributing to long-term shareholder value through market expansion and diversification into a stable procurement ecosystem.
About the Company
Established in 1993, Shukra Pharmaceuticals Ltd. operates in both manufacturing and trading pharmaceuticals, alongside offering laboratory testing services. The company has a market cap of over Rs 1,700 crore with a 3-year stock price CAGR of 260 per cent.
The company reported positive results in both quarterly and annual financial statements. In Q2FY26, the company reported net sales of Rs 5.88 crore and net profit of Rs 2.38 crore. In FY25, the company did net sales of Rs 32.59 crore and net profit of Rs 9.58 per share.
According to the shareholding, the promoters own a 50.95 per cent stake in the company while DIIs own 0.11 per cent and the public owns 48.94 per cent as of September 2025. The stock gave multibagger returns of 4,600 per cent in 3 years and a whopping 21,500 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.